Kiniksa Pharmaceuticals International (KNSA) Assets Average (2018 - 2026)

Kiniksa Pharmaceuticals International's Assets Average history runs 9 years deep, the most recent figure standing at $794.5 million for Q1 2026.

• Quarterly Assets Average rose 34.67% year-over-year to $794.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $794.5 million (up 34.67% YoY) and the FY2025 annual result came in at $672.1 million, up 21.44% from the prior year.
• Assets Average was $794.5 million for Q1 2026 at Kiniksa Pharmaceuticals International, up from $738.0 million in the prior quarter.
• Across five years, Assets Average topped out at $794.5 million in Q1 2026 and bottomed at $220.8 million in Q2 2022.
• A 5-year average of $515.4 million and a median of $523.0 million in 2024 frame the typical range for Assets Average.
• Annual changes were most pronounced in 2022 — Assets Average dropped 29.8% — and 2023, when it jumped 109.99%.
• Kiniksa Pharmaceuticals International's Assets Average stood at $459.8 million in 2022, then climbed by 9.76% to $504.7 million in 2023, then rose by 12.53% to $567.9 million in 2024, then grew by 29.94% to $738.0 million in 2025, then gained by 7.65% to $794.5 million in 2026.
• Business Quant data shows KNSA's Assets Average at $794.5 million in Q1 2026, $738.0 million in Q4 2025, and $686.7 million in Q3 2025.